{"filings":[{"id":94482,"accession_number":"0001658247-26-000039","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics Q1 2026: PALSONIFY net revenue $10.3M; EU approval; net loss $127.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PALSONIFY net product revenue $10.3M in Q1 2026, up from $5.4M in Q4 2025; 232 enrollment forms received.","European Commission approved PALSONIFY for acromegaly in April 2026; MAA submitted to Brazil, NDA in Japan.","Net loss $127.8M vs $96.8M in Q1 2025; cash $1.3B after $380M equity offering.","Initiated BALANCE-CAH Phase 2/3 trial; on track to start Phase 2/3 trial for atumelnant in Cushing's in Q2 2026.","2026 GAAP operating expense guidance $600M-$650M; non-GAAP $480M-$520M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":10734000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94481,"accession_number":"0001658247-26-000022","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Crinetics COO Jeff Knight resigns, enters consulting agreement at $400/hr","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Knight resigned as Chief Development and Operating Officer effective April 10, 2026 (previously reported March 23, 2026).","1-year consulting agreement with $400/hour rate, max 20 hours/month, renewable for 6 months.","Unvested restricted stock units and options forfeited; vested options exercisable three months after consulting ends.","Consulting agreement includes a general release of all claims against the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106889,"accession_number":"0001658247-26-000020","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Crinetics' Chief Development and Operating Officer resigns effective April 10, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Knight resigns as Chief Development and Operating Officer, effective April 10, 2026.","Resignation is to pursue another opportunity; not related to any disagreement with the Company.","No successor named; Knight's duties and direct reports reassigned to other executive leadership team members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106888,"accession_number":"0001658247-26-000017","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Crinetics Pharmaceuticals dismisses auditor BDO, appoints PwC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed BDO on Feb 27, 2026; no disagreements or reportable events for FY2024/2025.","BDO's reports on FY2024 and FY2025 financial statements were unqualified.","PwC appointed as new independent auditor for the fiscal year ending Dec 31, 2026.","No consultations with PwC prior to appointment regarding accounting principles or audit opinions.","BDO provided a letter to the SEC agreeing with the disclosures, attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106887,"accession_number":"0001658247-26-000011","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics Q4 2025: Palsonify launch revenue $5.4M, net loss $122.8M; EU CHMP positive opinion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PALSONIFY net product revenue $5.4M in Q4 2025; >200 enrollment forms by Dec end; 125+ HCPs prescribed in Q4.","CHMP adopted positive opinion recommending EU marketing authorization for paltusotine in acromegaly; EC decision pending.","Seamless Phase 2/3 EQUILIBRIUM study of atumelnant in Cushing's syndrome to start H1 2026; Phase 3 trials for CAH and carcinoid syndrome initiated.","Full-year 2025 net loss $465.3M; cash used $326.2M, below guidance; cash $1.0B at Dec 31, 2025 (pro forma $1.4B post Jan 2026 offering).","2026 GAAP OpEx guidance $600-650M; non-GAAP OpEx $480-520M; R&D and SG&A investments continue."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":7696000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106886,"accession_number":"0001658247-26-000003","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Crinetics changes Jeff Knight's title from COO to Chief Development and Operating Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Title change effective January 2, 2026; responsibilities expanded.","No change to Jeff Knight's compensation arrangements.","No arrangements or family relationships with other executives or directors.","Business experience described in prior proxy statement remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106885,"accession_number":"0001193125-26-011872","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Crinetics reiterates preliminary Q4 2025 PALSONIFY net product revenue over $5.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue from PALSONIFY (paltusotine) exceeds $5.0M for Q4 2025.","Audited FY2025 financials not yet available; estimates are preliminary and unaudited.","CEO Scott Struthers presents company update at J.P. Morgan Healthcare Conference on Jan 13, 2026.","Corporate slide presentation furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":7696000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106884,"accession_number":"0001193125-26-006421","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Crinetics prices $350M common stock offering at $45.95/share to fund PALSONIFY launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing: 7,620,000 shares at $45.95/share; gross proceeds ~$350M.","Underwriters granted 30-day option to buy up to 1,143,000 additional shares.","Net proceeds expected ~$330.2M, or ~$379.8M if option exercised.","Proceeds to fund commercial launch of PALSONIFY, R&D, and general corporate purposes.","Offering expected to close January 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106883,"accession_number":"0001193125-26-002368","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Crinetics PALSONIFY Q4 net revenue >$5M; atumelnant Phase 2 CAH shows 67% A4 reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited Q4 2025 PALSONIFY net product revenue exceeded $5.0M, with >200 enrollment forms and >125 unique prescribers.","Atumelnant 80mg in CAH cohort 4: 67% mean reduction in androstenedione, 88% of patients achieved physiologic glucocorticoid doses.","No serious adverse events or hepatic transaminase AEs in cohort 4 or open-label extension (25 patients, >750 weeks cumulative exposure).","About half of new PALSONIFY bottles reimbursed without Quickstart bridge; 12-month prior authorizations typical.","Crinetics hosts investor call today 8:30 AM ET to discuss results and outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123212,"accession_number":"0001658247-25-000022","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Crinetics CMO Dana Pizzuti steps down; transitions to advisor roles with $577k severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Dana Pizzuti steps down as CMO effective Dec 31, 2025; serves as Strategic Regulatory and Development Advisor through Mar 31, 2026.","Severance of $577,000 (12 months base salary) plus COBRA reimbursement and up to $15,000 in legal fees.","Advisor engagement from Apr 1, 2026 to Mar 30, 2028; $600/hour, up to 20 hours/month; equity continues to vest.","Transition duties include EU MAA approval for paltusotine (acromegaly), Brazil submission, and SKK Japanese application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123211,"accession_number":"0001658247-25-000018","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics Q3 net loss $130.1M; PALSONIFY launched for acromegaly after FDA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PALSONIFY (paltusotine) approved by FDA Sept 25 for first-line acromegaly; ~95% of top-priority HCP targets called, ~50% of filled prescriptions reimbursed.","Q3 2025 net loss $130.1M vs $76.8M YoY; R&D $90.5M (+46%), SG&A $52.3M (+102%) driven by launch and pipeline.","Cash, equivalents and investments $1.1B; cash burn guidance $340-370M for 2025; runway into 2029.","Phase 3 CAREFNDR (carcinoid syndrome) and Phase 3 CALM-CAH (CAH) expected to start Q4 2025; Phase 1/2 CRN09682 also Q4.","TSHR antagonist program shifted to alternative candidate; SST3 IND postponed after preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1535000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139883,"accession_number":"0001658247-25-000008","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Crinetics gets FDA approval for PALSONIFY (paltusotine) as first oral acromegaly treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved PALSONIFY (paltusotine) for adults with acromegaly with inadequate response to surgery or not surgical candidates.","First once-daily oral SST2 agonist; approval based on Phase 3 PATHFNDR-1/2 trials showing rapid, durable biochemical control and reduced symptom burden.","Product expected available in U.S. early October; CrinetiCARE support program launched for patients.","MAA under review in EU (CHMP opinion H1 2026); also evaluating paltusotine in Phase 3 CAREFNDR trial for carcinoid syndrome.","Investor conference call on Sept 25, 2025 at 6:00 pm ET to discuss FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139882,"accession_number":"0001193125-25-175494","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics reports Q2 net loss $115.6M; PDUFA for paltusotine on Sept 25, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.0M (vs $0.4M in Q2 2024); net loss widened to $115.6M from $74.1M YoY.","Cash, cash equivalents & investments $1.2B as of June 30, 2025; expected runway into 2029.","Paltusotine NDA PDUFA target action date September 25, 2025 for acromegaly; EMA review expected H1 2026.","Upcoming Phase 3 starts in H2 2025 for paltusotine in carcinoid syndrome and atumelnant in CAH (adult and pediatric).","2025 cash used in operations guided at $340-370M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1392000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157478,"accession_number":"0000950170-25-091613","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Crinetics to present 8 abstracts at ENDO 2025, including long-term paltusotine data and Phase 2 CAH results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight abstracts at ENDO 2025 (July 12-15, San Francisco) covering PALSONIFY (paltusotine), atumelnant, and CRN12755.","Oral presentation of long-term PATHFNDR-1 open-label extension data for paltusotine in acromegaly, showing durable biochemical and symptom control.","Phase 2 open-label trial results for atumelnant in congenital adrenal hyperplasia featured as oral presentation; data on adrenal volume and androgen reductions.","Early-stage pipeline data on CRN12755, a TSHR antagonist for Graves' hyperthyroidism and orbitopathy, also to be presented.","PALSONIFY conditionally approved as trade name by FDA; atumelnant Phase 2 interim results show rapid reductions in androstenedione and 17-hydroxyprogesterone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157477,"accession_number":"0000950170-25-090405","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Crinetics R&D Day updates preclinical pipeline: TSHR antagonist, SST3 agonist, NDC platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CRN12755 (TSHR antagonist) decreased thyroid hormone (T4) in rat model and hyaluronic acid/IL-6 in TED patient orbital fibroblasts.","CRN10329 (SST3 agonist) reduced cystic index, kidney weight, and injury markers in ADPKD mouse model; SST3 highly expressed in cyst-lining cells.","CRN09682 (NDC) showed dose-dependent anti-tumor activity in mouse models; free MMAE persisted in tumor >240 hours, cleared from plasma by 24 hours.","Phase 1/2 BRAVESST2 trial of CRN09682 expects up to 150 participants; Phase 1 dose escalation: 3-6 patients per cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157476,"accession_number":"0000950170-25-085442","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Crinetics shareholders elect directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors R. Scott Struthers (69.6M for), Matthew K. Fust (67.6M for), and Rogério Vivaldi Coelho (68.9M for), each with ~3.6M broker non-votes.","Ratified BDO USA as independent auditor for FY2025: 88.7M for, 129K against, 59.7K abstentions, no broker non-votes.","Advisory vote approved named executive officer compensation: 82.7M for, 2.6M against, 20.9K abstentions, ~3.6M broker non-votes.","Approximately 95% of outstanding shares (88.9M shares) were present or represented by proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157475,"accession_number":"0000950170-25-066939","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics Q1 net loss $96.8M; cash $1.3B; paltusotine PDUFA Sept 25, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $96.8M for Q1 2025 vs. $66.9M in Q1 2024, driven by higher R&D and SG&A costs.","Revenue $0.4M, down from $0.6M; primarily from Sanwa Kagaku licensing agreement.","Cash, equivalents, and investments $1.3B, expected to fund operations into 2029.","Paltusotine NDA under FDA review with PDUFA target action date Sept 25, 2025.","Phase 3 CALM-CAH study of atumelnant in CAH to begin H2 2025; R&D Day June 26."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":361000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157474,"accession_number":"0000950170-25-051179","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Former CFO Marc Wilson transitions to consultant role through April 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wilson resigned as employee on April 1, 2025, and entered a consulting agreement through April 1, 2026, with a possible six-month extension.","He will receive $300 per hour for services plus reimbursement of reasonable out-of-pocket expenses.","Outstanding equity awards continue vesting during consulting period; accelerates upon termination without cause, death, disability, or change in control.","The agreement includes a general release of claims against the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175860,"accession_number":"0000950170-25-029040","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics reports FY2024 net loss $298.4M; cash $1.4B; paltusotine PDUFA Sept 25, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024: $80.6M vs $60.1M YoY; full year $298.4M vs $214.5M.","Revenue fell to $1.0M in 2024 from $4.0M in 2023; no Q4 revenue.","Cash $1.4B at Dec 31, 2024, up from $558.6M; includes $925M in equity financings.","PDUFA target action date for paltusotine (acromegaly) set for Sept 25, 2025.","Plan to start Phase 3 paltusotine in carcinoid syndrome Q2 2025 and four IND filings in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":1039000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175859,"accession_number":"0000950170-25-025248","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Crinetics appoints Tobin Schilke as CFO effective Feb 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tobin Schilke appointed CFO effective February 28, 2025, succeeding Marc Wilson.","Schilke was previously CFO at Revance Therapeutics (2018-2025) and Achaogen.","Base salary $540,000; target bonus 40% of salary; inducement grant of 52,000 RSUs and option for 80,000 shares.","Marc Wilson's departure was previously announced in August 2024 for personal reasons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175858,"accession_number":"0000950170-25-005435","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Crinetics outlines 2025 milestones: paltusotine PDUFA Sept 25, atumelnant Ph3 start H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paltusotine NDA under FDA review; PDUFA target action date set for September 25, 2025.","Atumelnant Phase 3 initiation for adult CAH patients expected in H1 2025; pediatric CAH and Cushing's disease later-stage trials planned in 2025.","Four development candidates advancing toward IND-enabling studies for NETs, hyperparathyroidism, Graves' disease, thyroid eye disease, and ADPKD.","CEO Scott Struthers presenting at 43rd J.P. Morgan Healthcare Conference on January 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175857,"accession_number":"0000950170-25-003801","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Crinetics' atumelnant Phase 2 CAH trial meets primary endpoint with up to 80% mean A4 reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atumelnant reduced androstenedione up to 80% (120mg, p<0.0001); 80mg dose reduced by 774 ng/dL (p<0.0001).","Normalized testosterone in 8/13 females; 6 of 11 impacted participants resumed menses during the 12-week study.","Total adrenal volume consistently reduced across all dose cohorts; polycythemia resolved in 5 of 6 impacted participants.","No treatment-related severe or serious AEs; no dose reductions or discontinuations; most common AEs were headache (7/28) and fatigue (5/28).","Crinetics plans to initiate a global Phase 3 pivotal trial in adults and a Phase 2b/3 pediatric study in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192761,"accession_number":"0000950170-24-136680","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Crinetics appoints Isabel Kalofonos as CCO ahead of paltusotine launch","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Isabel Kalofonos named Chief Commercial Officer, effective Dec 16, 2024; leads paltusotine (once-daily SST2 agonist for acromegaly) launch prep and pipeline commercialization.","Compensation: $500k base salary, 40% target bonus; severance includes 9-month base pay (12-month + full target bonus if change in control within 12 months).","Expected Jan 10, 2025 grant of stock option for 100,000 shares; 25% vests Dec 16, 2025, remainder in 36 monthly installments.","Ms. Kalofonos previously CCO at Fulcrum Therapeutics; led ELAHERE launch at ImmunoGen and TAKHZYRO global launch at Takeda/Shire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192760,"accession_number":"0000950170-24-134342","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Crinetics announces FDA acceptance of NDA for paltusotine in acromegaly; PDUFA Sept 25, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Crinetics' NDA for once-daily oral paltusotine for adult acromegaly patients.","PDUFA target action date set for September 25, 2025; no advisory committee meeting planned.","NDA included Phase 3 PATHFNDR-1 and PATHFNDR-2 trials evaluating safety and efficacy.","Paltusotine granted Orphan Drug Designation by FDA in July 2020 for acromegaly.","If approved, paltusotine would be first once-daily oral SST2 nonpeptide agonist for acromegaly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192759,"accession_number":"0000950170-24-125361","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics reports Q3 net loss $76.8M; submits NDA for paltusotine; raises $575M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $76.8M in Q3 2024 vs $57.5M in Q3 2023; revenue $0 vs $0.3M from SKK licensing.","NDA submitted for paltusotine (oral somatostatin agonist) for acromegaly; FDA decision expected Dec 2024.","Upsized public offering raised $575M gross; pro-forma cash ~$1.4B, funding operations into 2029.","Four candidates in IND-enabling studies; first NDC platform candidate data at NANETS Nov 2024; TSH antagonist IND expected 2025.","R&D expenses $61.9M (+41% YoY); G&A $25.9M (+67% YoY), driven by pipeline expansion and launch prep."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1039000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192758,"accession_number":"0001193125-24-238120","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Crinetics COO James Hassard departs; consulting deal through Jan 2025 at $200/hr","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Hassard ceased as COO effective Oct 14, 2024; consulting and separation agreements signed Oct 10.","Consulting agreement: up to 20 hrs/month at $200/hr through Jan 15, 2025 for commercial launch prep.","Separation agreement provides payments/benefits for termination without cause per employment contract.","Outstanding equity awards continue to vest through Jan 15, 2025; prior employment agreement terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192757,"accession_number":"0001193125-24-235275","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Crinetics prices upsized $500M public offering at $50/share; net proceeds ~$472M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 10,000,000 shares of common stock at $50.00/share for gross proceeds of $500.0 million.","Net proceeds estimated at approximately $472.0 million (or ~$542.9 million if 1.5M share option exercised).","Underwriters granted 30-day option to purchase up to 1,500,000 additional shares; closing expected October 10, 2024.","Proceeds to fund R&D of clinical-stage candidates, pre-commercialization activities, and general corporate purposes.","Leerink Partners and Morgan Stanley acting as joint bookrunning managers for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209200,"accession_number":"0000950170-24-109644","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Crinetics submits NDA to FDA for paltusotine for acromegaly; Phase 3 data support submission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA supported by 18 clinical trials including two Phase 3 PATHFNDR studies; all primary and secondary endpoints met.","FDA notification on NDA acceptance expected in December 2024.","Paltusotine is first once-daily oral SST2 nonpeptide agonist in development for acromegaly.","Drug also in Phase 2 for carcinoid syndrome associated with neuroendocrine tumors.","CEO states submission is a key step toward delivering a new therapy for the acromegaly community."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209199,"accession_number":"0000950170-24-107259","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Crinetics CCO James Hassard to depart effective October 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Hassard separates as Chief Commercial Officer; last day October 14, 2024.","Hassard will receive severance per Employment Agreement for termination without cause, subject to release.","No replacement for CCO role announced by Crinetics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209198,"accession_number":"0000950170-24-093951","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Crinetics Q2 net loss $74.1M; CFO Wilson departs; paltusotine NDA on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $74.1M in Q2 2024 vs $51.0M in Q2 2023; R&D expenses rose to $58.3M from $40.6M.","CFO Marc Wilson stepping down for personal reasons; search for successor initiated; he will remain until replacement on-boarded.","Paltusotine NDA for acromegaly on track for H2 2024; Phase 3 program for carcinoid syndrome expected to begin by end of 2024.","Topline data from atumelnant Phase 2 studies in CAH and Cushing's syndrome anticipated by end of 2024.","Unrestricted cash $863M as of June 30, 2024; management expects funding into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":1039000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227120,"accession_number":"0001193125-24-165903","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Crinetics enters ATM equity offering agreement for up to $350M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement registering up to $350M in common stock sales.","Agents Leerink Partners and Cantor Fitzgerald will receive 3.0% commission per share sold.","No minimum sales required; sales made via 'at-the-market' methods under Rule 415.","Agreement dated June 21, 2024; no escrow or trust arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227119,"accession_number":"0000950170-24-071354","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Crinetics shareholders re-elect directors, ratify auditor, approve NEO pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Camille Bedrosian elected with 50.8M votes for (77%), 14.9M withheld; Dr. Wendell Wierenga with 50.3M for (76%).","Ratified BDO USA as independent auditor for FY 2024: 68.0M for, 0.1M against, 16.0K abstain.","Advisory vote on named executive officer compensation approved: 64.1M for, 1.7M against, 6.0K abstain, 2.3M broker non-votes.","Approximately 78.7M shares (86% of eligible) voted at the June 7, 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227118,"accession_number":"0001193125-24-153075","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Crinetics posts positive Phase 2 data for atumelnant; paltusotine NDA on track for 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atumelnant: 100% of CAH (n=6) achieved A4 below ULN; 100% of ADCS (n=5) normalized UFC at 80 mg once daily.","Paltusotine: PATHFNDR-2 met primary endpoint – 56% on drug vs 5% placebo achieved IGF-1 ≤1.0xULN (p<0.0001).","PATHFNDR-1 PRO analysis: paltusotine reduced breakthrough symptom exacerbations vs prior injectable SRLs.","Long-term ACROBAT Advance: stable IGF-1, symptom control, and safety at up to 42 months.","Crinetics expects to complete NDA submission for paltusotine in 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227117,"accession_number":"0001193125-24-144484","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Crinetics announces early release of ENDO 2024 late-breaking abstracts for atumelnant Phase 2 CAH study","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Late-breaking abstracts for atumelnant (CRN04894) Phase 2 CAH study released before embargo.","Abstract contained summary data on 4 subjects; data from 6 subjects in cohort 1 and cohort 2 to be presented June 3, 2024.","Full data set will be presented at ENDO 2024 poster session on June 1-2 pm ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227116,"accession_number":"0000950170-24-056977","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics Q1 net loss $66.9M; paltusotine NDA on track for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $66.9M in Q1 2024 vs $46.0M in Q1 2023; revenue fell to $0.6M from $2.7M.","Cash, equivalents, and investments total $901.0M as of March 31, 2024, partly from $350M private placement in Feb.","Paltusotine PATHFNDR-2 Phase 3 met primary and all secondary endpoints; NDA submission expected in 2H 2024.","Initial atumelnant Phase 2 results in CAH and Cushing's to be presented at ENDO 2024 (June 1-4).","Plan to initiate paltusotine Phase 3 in carcinoid syndrome by end of 2024 pending FDA discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":640000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227115,"accession_number":"0000950170-24-055872","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Crinetics to present initial atumelnant Phase 2 data in CAH and Cushing's at ENDO 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five abstracts, four late-breaking, to be presented at ENDO 2024 (June 1-4, Boston).","Initial Phase 2 TouCAHn data: atumelnant shows rapid, profound reductions in androstenedione and 17-hydroxyprogesterone in classic congenital adrenal hyperplasia.","Phase 1b/2a data on atumelnant in ACTH-dependent Cushing's shows first evidence of rapid, sustained cortisol reductions.","Phase 3 PATHFNDR-2 paltusotine data in medically untreated acromegaly patients to be presented; PATHFNDR-1 patient-reported symptoms and long-term safety also featured.","Crinetics plans to submit paltusotine NDA later in 2024; CEO cites major milestone for pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227114,"accession_number":"0001193125-24-087326","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Crinetics adopts non-qualified deferred compensation plan for executives and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan effective April 1, 2024; allows deferral of salary, fees, bonuses, and time-based RSUs.","Participation limited to select management, highly compensated employees, and non-employee directors.","Company may make matching or discretionary contributions; elective deferrals and matching fully vested.","Payments generally made after separation from service or at elected in-service payment date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246016,"accession_number":"0001193125-24-070706","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Crinetics paltusotine meets all endpoints in Phase 3 acromegaly study; NDA planned 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: 56% of paltusotine patients achieved IGF-1 ≤1.0 xULN vs 5% placebo (p<0.0001).","All secondary endpoints met: IGF-1 change, GH <1.0 ng/mL, and Acromegaly Symptoms Diary score.","No serious adverse events reported; common TEAEs included diarrhea, headache, arthralgia, abdominal pain.","Crinetics to submit NDA to FDA in 2H 2024; potential launch in 2025.","PATHFNDR-2 enrolled 111 untreated acromegaly patients in a 24-week placebo-controlled trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246015,"accession_number":"0001193125-24-065913","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Crinetics reports positive Phase 2 results for paltusotine in carcinoid syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial: 63% reduction in mean flushing frequency (p<0.0001) for patients with >1/day at baseline.","60% reduction in mean excess bowel movements (p=0.02) for patients with >3/day at baseline; 61% reduction in flushing severity (p<0.0001).","Paltusotine generally well-tolerated; no treatment-related severe or serious AEs; common AEs included diarrhea, abdominal pain, nausea, headache.","Company plans to engage FDA to align on Phase 3 design; expects to initiate Phase 3 program by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246014,"accession_number":"0001193125-24-055935","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Crinetics raises $350M in oversubscribed private placement of 8.33M shares at $42/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 8,333,334 common shares at $42.00/share raises ~$350M gross proceeds.","Oversubscribed placement includes new and existing investors like Adage Capital, Driehaus, EcoR1, Janus Henderson.","Net proceeds to fund R&D of clinical-stage candidates, working capital, and general corporate purposes.","Closing expected March 1, 2024; resale registration statement to be filed within 40 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246013,"accession_number":"0000950170-24-022068","cik":1658247,"company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crinetics reports Q4 net loss of $60.1M; announces $350M private placement; paltusotine NDA on track for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2023 was $60.1M vs $45.0M in Q4 2022; full-year net loss $214.5M vs $163.9M in 2022.","Cash, equivalents, and investments totaled $558.6M as of Dec 31, 2023; $350M private placement extends runway into 2028.","Phase 3 PATHFNDR-2 topline results for paltusotine in acromegaly expected March 2024; NDA submission planned 2H 2024.","Phase 2 paltusotine in carcinoid syndrome full topline results expected 1H 2024; initial data from 27 patients reported Dec 2023.","R&D expenses rose to $168.5M for FY2023 from $130.2M in FY2022, driven by higher personnel and outside services costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4013000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3871764550.2256045,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}